Tri Trembolic – Trenbolone Blend 150 mg/mL | 10 mL Vial
1. Product Overview
Tri Trembolic is presented as an injectable anabolic-androgenic steroid preparation containing three different trenbolone esters.
According to the supplied Roidsdeal short description, the product contains trenbolone acetate, trenbolone enanthate, and trenbolone cyclohexylmethylcarbonate.
The formulation has a declared combined concentration of 150 mg/mL and is packaged in a 10 mL vial.
Based on these specifications, the calculated total combined trenbolone ester content is 1,500 mg per vial.
The supplied description identifies Nitro Lab as the manufacturer.
However, no original manufacturer label or independent documentation has been provided to confirm this identity.
Trenbolone is a synthetic anabolic-androgenic steroid belonging to the 19-nortestosterone family.
Different trenbolone esters have different physicochemical properties that can influence their release characteristics in appropriately formulated preparations.
The combination of multiple esters may result in different release components.
However, the exact pharmacokinetic profile of Tri Trembolic cannot be established without knowing the individual ester concentrations and complete formulation.
Trenbolone has been associated with veterinary applications and experimental research.
It is not an FDA-approved medication for human therapeutic use.
The supplied information does not establish that Tri Trembolic is an authorized pharmaceutical or veterinary preparation.
No Roidsdeal long description or Finest Gears product description has been supplied.
This description therefore distinguishes the declared product specifications from general scientific information about trenbolone and its esters.
2. What Is Tri Trembolic?
Tri Trembolic is the commercial name used for a three-ester trenbolone preparation described in the supplied Roidsdeal product data.
The three declared active ingredients are:
Trenbolone Acetate
Trenbolone acetate is an esterified form of trenbolone.
The acetate ester is associated with relatively shorter release characteristics compared with longer-chain trenbolone esters.
Certain trenbolone acetate formulations have been used in regulated veterinary applications.
Trenbolone Enanthate
Trenbolone enanthate is another esterified form of trenbolone.
The enanthate ester has different physicochemical characteristics from the acetate ester and is generally associated with more prolonged release behavior in depot formulations.
No FDA-approved human therapeutic indication has been established for trenbolone enanthate.
Trenbolone Cyclohexylmethylcarbonate
Trenbolone cyclohexylmethylcarbonate is a longer-chain esterified form of trenbolone.
It is also commonly associated with the name trenbolone hexahydrobenzylcarbonate.
The precise chemical identity should be confirmed against the manufacturer’s documentation.
Combined Ester Formulation
All three declared ingredients are esterified derivatives of trenbolone.
Following ester hydrolysis, they release trenbolone, which can interact with androgen receptors.
The individual concentrations of the three esters are not specified.
Therefore, the product should not be assumed to contain equal amounts of each ester.
The declared 150 mg/mL concentration refers to their combined ester mass.
3. How Does the Trenbolone Blend Work?
The pharmacological activity of trenbolone ester preparations is associated with trenbolone following ester hydrolysis.
Ester Hydrolysis
Trenbolone acetate, enanthate, and cyclohexylmethylcarbonate contain different ester groups.
These groups influence physicochemical properties and release characteristics.
Following hydrolysis, the underlying trenbolone molecule becomes available for androgen receptor interaction.
Androgen Receptor Activation
Trenbolone acts as an androgen receptor agonist.
Androgen receptors influence gene expression and participate in biological processes involving muscle, reproductive tissues, and other hormone-responsive systems.
Multiple Ester Characteristics
The three declared esters have different release characteristics.
However, their individual concentrations have not been supplied.
Consequently, no reliable product-specific release profile, onset, or duration can be established.
Anabolic-Androgenic Activity
Trenbolone has demonstrated anabolic-androgenic activity in experimental and veterinary contexts.
These findings do not establish safe or effective human therapeutic use.
19-Nortestosterone Structure
Trenbolone belongs to the 19-nortestosterone class of synthetic steroids.
Its structure differs from testosterone and influences its pharmacological characteristics.
Aromatization
Trenbolone is not conventionally converted into estradiol through aromatase activity.
However, this does not eliminate endocrine disturbances or other adverse effects.
Endocrine Feedback
Exogenous anabolic-androgenic steroids can suppress hypothalamic-pituitary-gonadal axis activity.
This may reduce endogenous testosterone production and interfere with reproductive function.
Cardiovascular Effects
Anabolic-androgenic steroid exposure may adversely affect lipid metabolism, blood pressure, and cardiovascular health.
The exact risks associated with this particular formulation have not been clinically established.
4. Medical Uses & Clinical Information
Trenbolone has primarily been associated with veterinary applications and experimental research.
It has no established FDA-approved therapeutic indication for humans.
Veterinary Applications
Certain trenbolone acetate-containing products have been used in regulated veterinary contexts, including cattle growth-promoting implants.
These applications do not establish suitability for human administration.
Androgen Receptor Research
Trenbolone has been investigated for its interaction with androgen receptors.
These studies contribute to scientific understanding of synthetic androgen activity.
Anabolic Physiology Research
Experimental research has examined anabolic-androgenic steroids in relation to muscle and protein metabolism.
Such findings should not be interpreted as evidence supporting nonmedical human use.
Endocrine Regulation
Trenbolone exposure may influence endocrine feedback mechanisms.
Suppression of endogenous hormone production is an important biological concern.
Reproductive Physiology
Exogenous androgen exposure can interfere with reproductive endocrine regulation.
Potential effects on fertility and gonadal function are relevant safety considerations.
Cardiovascular Research
Anabolic-androgenic steroids have been studied in relation to cardiovascular risk factors.
Potential concerns include adverse lipid changes, elevated blood pressure, and other cardiovascular complications.
Behavioral Research
Synthetic androgen exposure has been investigated for possible effects on behavior and neuroendocrine signaling.
However, controlled human-specific evidence for trenbolone remains limited.
Multi-Ester Preparations
Combining multiple esters changes the formulation’s physicochemical characteristics.
However, there is no supplied product-specific evidence establishing the pharmacokinetic behavior of Tri Trembolic.
Human Therapeutic Status
Trenbolone and its esters are not FDA-approved medications for testosterone replacement therapy, muscle disorders, or other human medical conditions.
Clinical Limitations
No product-specific clinical studies evaluating Tri Trembolic have been supplied.
The available information does not establish human therapeutic efficacy, pharmaceutical quality, or an acceptable safety profile.
Veterinary or experimental research should not be interpreted as evidence supporting human administration of this commercial product.
5. Product Specifications & Packaging
| Specification | Details |
|---|---|
| Product Name | Tri Trembolic |
| Brand | Not Independently Confirmed |
| Listed Manufacturer | Nitro Lab |
| Manufacturer Verification | Required |
| Active Ingredient 1 | Trenbolone Acetate |
| Active Ingredient 2 | Trenbolone Enanthate |
| Active Ingredient 3 | Trenbolone Cyclohexylmethylcarbonate |
| Compound Classification | Anabolic-Androgenic Steroid |
| Chemical Classification | Esterified 19-Nortestosterone Derivatives |
| Declared Combined Concentration | 150 mg/mL |
| Individual Ester Concentrations | Not Specified |
| Dosage Form | Injectable Preparation |
| Declared Package Volume | 10 mL |
| Packaging Presentation | Vial |
| Calculated Total Combined Ester Content | 1,500 mg (1.5 g) |
| Free Trenbolone Equivalent | Cannot Be Determined from Available Data |
| Product Category | Injectable Anabolic Steroids |
| Carrier Oil / Vehicle | Not Specified |
| Excipients | Not Specified |
| Aromatization | Not Conventionally Aromatized |
| US Controlled Substance Status | Schedule III |
| WADA Status | Prohibited |
| FDA Approval for Human Treatment | Not Approved |
| Product-Specific Regulatory Authorization | Not Established |
| Batch-Specific COA | Not Provided |
| Sterility Testing | Not Provided |
| Actual Ingredient Concentrations | Not Independently Verified |
Declared Ester Composition
The Roidsdeal short description identifies three trenbolone esters.
However, it does not specify how the combined 150 mg/mL concentration is distributed among them.
| Trenbolone Ester | Individual Concentration |
|---|---|
| Trenbolone Acetate | Not Provided |
| Trenbolone Enanthate | Not Provided |
| Trenbolone Cyclohexylmethylcarbonate | Not Provided |
| Combined Total | 150 mg/mL (Declared) |
The formulation should not be assumed to contain 50 mg/mL of each ester without manufacturer confirmation.
No manufacturer-specific analytical report, sterility testing, or complete formulation documentation has been supplied.
6. Administration & Medical Supervision
Tri Trembolic is described as an injectable trenbolone ester blend.
Trenbolone is a pharmacologically active synthetic anabolic-androgenic steroid.
It is not FDA-approved for human therapeutic use.
The supplied documentation does not establish an authorized human dosing regimen for this product.
The declared 150 mg/mL concentration identifies the claimed combined amount of trenbolone esters per milliliter.
It does not represent a recommended or medically appropriate dose.
No injection procedure, administration schedule, bodybuilding cycle, or performance-enhancement regimen is supported by the supplied information.
The individual ester concentrations and exact formulation are unknown.
These limitations prevent reliable assessment of product-specific pharmacokinetic characteristics.
Veterinary use of certain trenbolone acetate products does not establish suitability for human administration.
The actual ingredient content, sterility, and pharmaceutical quality of this commercial product have not been independently verified.
It should not be assumed suitable for human injection based solely on the supplied short description.
7. Possible Side Effects & Safety Limitations
Trenbolone ester preparations may produce adverse effects associated with anabolic-androgenic steroid exposure.
Human-specific clinical safety data remain limited.
Endocrine and Reproductive Effects
Potential adverse effects include:
- Suppression of endogenous testosterone production
- Reduced sperm production
- Reduced fertility
- Testicular atrophy
- Hormonal disturbances
- Reproductive dysfunction
Cardiovascular and Metabolic Effects
Potential complications include:
- Elevated blood pressure
- Adverse cholesterol changes
- Cardiovascular complications
- Other metabolic disturbances
Androgenic Effects
Potential androgen-related effects include:
- Acne
- Oily skin
- Hair loss in susceptible individuals
- Increased body or facial hair growth
- Virilization in females
Psychological and Behavioral Effects
Anabolic-androgenic steroid exposure may be associated with:
- Mood changes
- Irritability
- Sleep disturbances
- Other behavioral disturbances
Reproductive Risks in Females
Androgen exposure can cause virilization, menstrual disturbances, and other reproductive effects.
Some androgenic changes may be irreversible.
Injectable Formulation Risks
Unverified injectable preparations may introduce additional risks involving:
- Microbial contamination
- Injection-site infection
- Incorrect ingredient concentrations
- Undisclosed excipients
- Formulation instability
- Sterility failures
Uncertain Human Safety Profile
Trenbolone does not have an established human therapeutic safety profile.
The actual frequency and severity of adverse effects associated with this specific Tri Trembolic product have not been established.
8. Warnings & Precautions
Trenbolone is a synthetic anabolic-androgenic steroid with clinically important safety concerns.
It is not approved by the FDA for human therapeutic use.
Exogenous anabolic-androgenic steroid exposure can alter normal endocrine regulation and suppress endogenous testosterone production.
Individuals with cardiovascular disease, reproductive-health concerns, or other medical conditions may face additional risks.
Potential cardiovascular concerns include adverse cholesterol changes, elevated blood pressure, and other complications.
Exposure during pregnancy may cause serious developmental harm.
Androgen exposure can cause virilization in females and interfere with normal development in adolescents.
Trenbolone and its esters are prohibited in competitive sport under WADA regulations.
In the United States, trenbolone is classified as a Schedule III controlled anabolic steroid.
The supplied description does not establish that Tri Trembolic is an authorized pharmaceutical or veterinary preparation.
Product identity, individual ester concentrations, actual combined concentration, formulation, sterility, manufacturing quality, and regulatory authorization require independent verification.
9. Storage & Handling
Tri Trembolic is described as a 10 mL vial product.
The supplied information does not provide verified manufacturer-specific storage temperatures, stability data, or expiration requirements.
Storage conditions for injectable anabolic-androgenic steroid preparations depend on the carrier vehicle, excipients, container closure system, and manufacturing process.
These details are not supplied.
Storage should follow authentic manufacturer documentation when available.
The product should remain in its original, clearly identified packaging.
Avoid environmental conditions that may compromise formulation stability or packaging integrity.
Keep the product away from children and unauthorized access.
A vial with damaged packaging, compromised seals, uncertain labeling, or unverified storage history should not be assumed safe for administration.
No product-specific in-use stability information has been supplied.
10. Frequently Asked Questions (FAQs)
What is Tri Trembolic?
Tri Trembolic is a product described by Roidsdeal as containing three trenbolone esters: acetate, enanthate, and cyclohexylmethylcarbonate.
What is the declared combined concentration?
Roidsdeal lists a combined concentration of 150 mg/mL. The individual ester concentrations have not been provided.
How much combined trenbolone ester content is included in one vial?
The product is described as a 10 mL vial containing a calculated total of 1,500 mg of combined trenbolone esters.
Does Tri Trembolic contain 50 mg/mL of each ester?
The supplied description does not specify individual ester concentrations. Equal proportions cannot be assumed without manufacturer confirmation.
Is Tri Trembolic approved for human medical treatment?
No FDA approval has been established for Tri Trembolic. Trenbolone and its esters are not FDA-approved medications for human therapeutic use.
11. Conclusion & Medical Disclaimer
Tri Trembolic is presented as an injectable three-ester trenbolone preparation containing trenbolone acetate, trenbolone enanthate, and trenbolone cyclohexylmethylcarbonate.
According to Roidsdeal, the product has a declared combined concentration of 150 mg/mL and is packaged in a 10 mL vial.
The calculated total combined trenbolone ester content is 1,500 mg per vial.
However, the individual ester concentrations have not been provided.
This prevents reliable determination of the formulation’s exact composition and free-trenbolone-equivalent content.
The supplied information identifies Nitro Lab as the manufacturer but does not provide independent confirmation.
No Roidsdeal long description or Finest Gears product description is available.
Product authenticity, actual ingredient concentrations, carrier vehicle, sterility, manufacturing quality, and regulatory authorization remain unverified.
Trenbolone is not approved for human therapeutic use by the FDA.
Medical Disclaimer: This information is provided for educational and product-identification purposes only. It does not constitute medical advice, injection guidance, dosage recommendations, or a recommendation for human use, bodybuilding, athletic performance enhancement, or treatment of any medical condition.




Reviews
There are no reviews yet.